TPST NASDAQ
Tempest Therapeutics, Inc.
1W: -2.1%
1M: -26.2%
3M: -24.2%
YTD: -72.5%
1Y: -92.0%
3Y: -81.7%
5Y: -94.4%
$0.81
+0.01 (+0.63%)
Weekly Expected Move ±39.8%
$0
$0
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (22)
Tempest signs related-party R&D pact, reshapes leadership
HC Wainwright Analysts Raise Earnings Estimates for TPST
Tempest Therapeutics announces $2.5M private placement
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
12 Health Care Stocks Moving In Friday's Intraday Session
New Strong Buy Stocks for April 10th
HC Wainwright Issues Optimistic Estimate for TPST Earnings
Brokers Set Expectations for TPST Q1 Earnings
Tempest Therapeutics GAAP EPS of -$6.33 misses by $0.23
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Matthew Angel Purchases 231,482 Shares of Tempest Therapeutics (NASDAQ:TPST) Stock
12 Health Care Stocks Moving In Monday's Intraday Session
Tempest Therapeutics announces up to $6M private placement
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Tempest Therapeutics (NASDAQ:TPST) Shares Scheduled to Split on Friday, January 30th
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules